Table 4 Crude 5-year disease-free survival and hazard ratiosa for recurrence or death for the total study population (n = 186)
Crude 5-year disease-free survival (%) | Hazard ratio for recurrence/death (95% CI) | |
|---|---|---|
Gender | ||
Male | 70 | 1.0 (reference) |
Female | 78 | 2.1 (1.1–4.0) |
Age | 1.1 (1.0–1.1) | |
≤ 65 | 90b | |
>66–75 | 75 | |
≥76 | 60 | |
Comorbidity | ||
0 | 89c | 1.0 (reference) |
1 | 64 | 3.3 (1.3–8.1) |
≥2 | 64 | 3.3 (1.4–7.9) |
Surgery | ||
Elective | 75 | 1.0 (reference) |
Acute | 1.7 (0.2–14.5) | |
Subsite | ||
Left-sided colon | 70 | 1.2 (0.6–2.3) |
Right-sided colon | 76 | 1.0 (reference) |
Differentiation grade | ||
Well/moderate | 82c | 1.0 (reference) |
Poor/undifferentiated | 52 | 3.7 (1.8–7.4) |
Lymph nodes evaluated | ||
<10 | 72 | 1.1 (0.6–2.2) |
≥10 | 76 | 1.0 (reference) |
Tumor obstruction | ||
No | 75 | 1.0 (reference) |
Yes | 62 | 1.5 (0.2–12.6) |
Tumor perforation | ||
No | 75 | 1.0 (reference) |
Yes | ∧ | 1.8 (0.5–6.6) |
Lymphangioinvasion | ||
No | 75c | 1.0 (reference) |
Yes | ∧ | 6.8 (2.1–21.8) |
Microsatellite status | ||
MSS | 78 c | 1.0 (reference) |
MSI | 60 | 1.6 (0.7–3.9) |
KRAS | ||
Wild type | 73 | 1.0 (reference) |
Mutant | 75 | 1.1 (0.5–2.1) |
BRAF | ||
Wild type | 77c | 1.0 (reference) |
Mutant | 57 | 1.1 (0.4–2.6) |
PIK3CA | ||
Wild type | 72 | 1.0 (reference) |
Mutant | ∧ | 0.5 (0.1–1.7) |